Distamycin A
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antineoplastic |
| Catalog number | BBF-01766 |
| CAS | 636-47-5 |
| Molecular Weight | 481.51 |
| Molecular Formula | C22H27N9O4 |
| Purity | 95% |
Online Inquiry
Description
It is produced by the strain of Streptomyces distallicus NCIB 8936. It has the activity against gram-positive bacterium, mycobacterium, dermatophyte and Trichophyte. It has inhibitory effects on solid tumors such as Epstein-Barr ascites carcinoma, sarcoma 180, Walker 258, oberling-Guerin osteoma, and also inhibits vaccinosis virus, herpes simplex virus, adenovirus, and mouse hepatitis virus in cell culture.
Specification
| Related CAS | 6576-51-8 (mono-hydrochloride) |
| Synonyms | Distamycin; Distamycin-3; stallimycin; Herperetin; DST-A; Estalimicina; Stallimicina; Stallimycinum; 2N-(3,3-aminoiminopropyl)-4-[4-(4-formamido-1-methyl-1H-2-pyrrolylcarboxamido)-1-methyl-1H-2-pyrrolylcarboxamido]-1-methyl-1H-2-pyrrolecarboxamide |
| Storage | Store at -20°C |
| IUPAC Name | N-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-formamido-1-methylpyrrole-2-carboxamide |
| Canonical SMILES | CN1C=C(C=C1C(=O)NC2=CN(C(=C2)C(=O)NC3=CN(C(=C3)C(=O)NCCC(=N)N)C)C)NC=O |
| InChI | InChI=1S/C22H27N9O4/c1-29-9-13(26-12-32)6-17(29)21(34)28-15-8-18(31(3)11-15)22(35)27-14-7-16(30(2)10-14)20(33)25-5-4-19(23)24/h6-12H,4-5H2,1-3H3,(H3,23,24)(H,25,33)(H,26,32)(H,27,35)(H,28,34) |
| InChI Key | UPBAOYRENQEPJO-UHFFFAOYSA-N |
Properties
| Appearance | White Acicular Crystal |
| Antibiotic Activity Spectrum | Gram-positive bacteria; Neoplastics (Tumor); Fungi; Mycobacteria; Viruses |
| Boiling Point | 579.2 °C (Predicted) |
| Melting Point | 183-185 °C (dec.) |
| Density | 1.45 g/cm3 |
| Solubility | Soluble in Ethanol |
Reference Reading
1.Energetics of ligand binding to G-quadruplexes.
Giancola C1, Pagano B. Top Curr Chem. 2013;330:211-42. doi: 10.1007/128_2012_347.
G-quadruplex ligands are potential anticancer agents as telomerase inhibitors and potential transcriptional regulators of oncogenes. The search for best-in-class drugs is addressed to identify small molecules able to promote and stabilize G-quadruplex structures. What features should the G-quadruplex ligands possess? They should have selective antiproliferative effects on cancer cells and induce telomerase inhibition or oncogene suppression. One of the main challenges in their design and synthesis is to make the ligands selective for G-quadruplex DNA. These features should be amplified by careful analyses of physico-chemical aspects of G-quadruplex-drug interactions. In particular, the study of the energetics of G-quadruplex-drug interactions can enhance drug design by providing thermodynamic parameters that give quantitative information on the biomolecular interactions important for binding. The main methodologies used to gain information on energetics of binding are based on spectroscopic or calorimetric principles.
2.Design and synthesis of novel distamycin-modified nucleoside analogues as HIV-1 reverse transcriptase inhibitors.
Li C1, Ma C2, Zhang J2, Qian N2, Ding J2, Qiao R3, Zhao Y4. Antiviral Res. 2014 Feb;102:54-60. doi: 10.1016/j.antiviral.2013.12.002. Epub 2013 Dec 14.
Design and synthesis of nucleoside analogues have persistently attracted extensive interest because of their potential application in the field of antiviral therapy, and its study also receives additional impetus for improvement in the ProTide technology. Previous studies have made great strides in the design and discovery of monophosphorylated nucleoside analogues as potential kinase-independent antiretrovirals. In this work, a series of nucleoside phosphoramidates modified by distamycin analogues was synthesized and evaluated as nucleoside reverse transcriptase inhibitors (NRTIs) in HIV-1-infected MT-4 and CEM cells, including variations in nucleoside, alkyl moiety, and the structure of distamycin analogues. These compounds exhibited modest potency with the EC50 value in the range of 1.3- to 6.5-fold lower than their corresponding parent drugs in MT-4 cells, which may be attributed to increasing intracellular availability due to the existence of distamycin analogue with favorable hydrophilic-lipophilic equilibrium.
3.Mining of the pyrrolamide antibiotics analogs in Streptomyces netropsis reveals the amidohydrolase-dependent "iterative strategy" underlying the pyrrole polymerization.
Hao C1, Huang S1, Deng Z2, Zhao C1, Yu Y3. PLoS One. 2014 Jun 5;9(6):e99077. doi: 10.1371/journal.pone.0099077. eCollection 2014.
In biosynthesis of natural products, potential intermediates or analogs of a particular compound in the crude extracts are commonly overlooked in routine assays due to their low concentration, limited structural information, or because of their insignificant bio-activities. This may lead into an incomplete and even an incorrect biosynthetic pathway for the target molecule. Here we applied multiple compound mining approaches, including genome scanning and precursor ion scan-directed mass spectrometry, to identify potential pyrrolamide compounds in the fermentation culture of Streptomyces netropsis. Several novel congocidine and distamycin analogs were thus detected and characterized. A more reasonable route for the biosynthesis of pyrrolamides was proposed based on the structures of these newly discovered compounds, as well as the functional characterization of several key biosynthetic genes of pyrrolamides. Collectively, our results implied an unusual "iterative strategy" underlying the pyrrole polymerization in the biosynthesis of pyrrolamide antibiotics.
4.Natural combinatorial biosynthesis involving two clusters for the synthesis of three pyrrolamides in Streptomyces netropsis.
Vingadassalon A1, Lorieux F, Juguet M, Le Goff G, Gerbaud C, Pernodet JL, Lautru S. ACS Chem Biol. 2015 Feb 20;10(2):601-10. doi: 10.1021/cb500652n. Epub 2014 Dec 4.
The pyrrolamides constitute a small family of secondary metabolites that are known for their ability to bind noncovalently to the DNA minor groove with some sequence specificity. To date, only a single pyrrolamide biosynthetic gene cluster has been reported, directing the synthesis of congocidine (netropsin) in Streptomyces ambofaciens. In this study, we improve our understanding of pyrrolamide biosynthesis through the identification and characterization of the gene cluster responsible for the production of distamycin in Streptomyces netropsis DSM40846. We discover that the strain produces two other pyrrolamides, the well-characterized congocidine and a congocidine/distamycin hybrid that we named disgocidine. S. netropsis DSM40846 genome analysis led to the identification of two distinct pyrrolamide-like biosynthetic gene clusters. We show here that these two clusters are reciprocally dependent for the production of the three pyrrolamide molecules.
Recommended Products
| BBF-03796 | Bambermycin | Inquiry |
| BBF-05730 | Abamectin | Inquiry |
| BBF-03819 | Spinosyn A | Inquiry |
| BBF-00852 | Epothilon B | Inquiry |
| BBF-03761 | Tunicamycin | Inquiry |
| BBF-03800 | Moxidectin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
